Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkBack PageHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 56

FDA Fast-Tracks Nelkarmi for Lung Cancers That Outsmarted Earlier Drugs

The FDA granted accelerated approval to Nelkarmi (neladalkib) for adults with advanced ALK-positive non-small cell lung cancer already treated with other ALK-targeted drugs. The once-daily pill shrank tumors in 49% of patients who had progressed on alectinib, giving a shrinking group of options a new one.

By the Paparazzi desk November 17, 2026 · 10:11 AM · curetoday.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: curetoday.com.
  • The source published it on Nov 17, 2026 at 10:11 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The FDA handed accelerated approval to Nelkarmi (neladalkib) on Nov. 17, clearing the once-daily pill for adults whose locally advanced or metastatic ALK-positive non-small cell lung cancer has already been treated with other ALK-targeted drugs. The green light covers patients whose disease can't be removed by surgery and who previously took either alectinib (Alecensa) or at least two ALK tyrosine kinase inhibitors plus platinum-based chemotherapy. Nelkarmi works by blocking the ALK protein that fuels the growth of these tumors.

The approval rests on ALKOVE-1, a single-arm trial in which every patient received Nelkarmi. Among 67 patients who had been treated with alectinib, tumors shrank in 49%; of those responders, 76% held that response for at least six months and 52% for at least a year. In the 155 patients who had already cycled through two or more ALK inhibitors and platinum-based chemotherapy, tumors shrank in 32%, with 69% of responders lasting at least six months and 51% at least a year.

Sponsored

That matters because ALK-positive lung cancers often quit responding to earlier ALK inhibitors as new mutations take hold, whittling down targeted choices. The FDA's accelerated pathway lets serious conditions get drugs based on early signs of benefit like tumor shrinkage, with continued approval potentially hinging on a confirmatory trial. The application got priority review, and neladalkib arrived with breakthrough therapy and orphan drug designations attached.

The label carries a hefty side-effect list. At least 20% of patients hit liver problems, muscle and bone pain, constipation, taste changes, peripheral neuropathy that can cause numbness or tingling, edema and fatigue. Prescribing information also flags liver damage, kidney problems, eye problems, rising creatine phosphokinase — an enzyme that can signal muscle damage — and possible harm to a developing baby. Patients are told to report vision changes, unexplained muscle pain or weakness, or liver-trouble signs like yellowing skin or dark urine, and to discuss birth control during treatment.

The recommended dose is 150 mg by mouth once a day, with or without food, at roughly the same time each day. Treatment runs until the cancer grows or the side effects become too much to handle.

TopicsNelkarmi · neladalkib · FDA · ALKOVE-1 · alectinib · Alecensa · ALK-positive non-small cell lung cancer · tyrosine kinase inhibitors

Share

Source: curetoday.com

Written by AI from verified reporting.

More stories

  • Health & science 33 minutes ago · yahoo.com · 0 views
    FDA clears GSK lung cancer drug for advanced cases
  • Health & science 50 minutes ago · techtimes.com · 0 views
    Pierre Fabre's lung cancer pill wins FDA fast track with no data public
  • Health & science 2 hours ago · apnews.com · 0 views
    US and Mexico stripped of measles-free status, international health officials say
  • Health & science 3 hours ago · cbsnews.com · 0 views
    China fires scientist after girl, 6, died in hidden gene-editing trial
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.